gms | German Medical Science

26th Annual Meeting of the German Retina Society

German Retina Society

27.09.2013, Hamburg

Stem cell therapy of age-related macular degeneration

Meeting Abstract

Search Medline for

  • Mahdy Ranjbar - Lübeck, Germany
  • S. Grisanti - Lübeck, Germany

Retinologische Gesellschaft. 26. Jahrestagung der Retinologischen Gesellschaft. Hamburg, 27.-27.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13rg04

doi: 10.3205/13rg04, urn:nbn:de:0183-13rg041

Published: August 20, 2013

© 2013 Ranjbar et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Introduction: Age-related macular degeneration (AMD) is the leading cause of blindness in people over age 55 in the developed world. Loss of retinal pigmented epithelium (RPE) plays a major pathophysiologic role in the disease. Stem cells are currently considered for RPEreplacement. Based on their level of differentiation and their potential they are classified in embryonal stem cells (ESC) and adult stem cells (ASC), while the latter group can be subclassified in induced pluripotent stem cells (iPSC) and natural pluripotent stem cells (nPSC).

Methods: On basis of the published literature these stem cell groups are evaluated with regard to their potential and feasibility of clinical application in the treatment of age-related macular degeneration.

Results: All these mentioned stem cell populations are able to generate RPE-like cells in terms of morphology and function. These findings have been demonstrated in vitro and in preclinical animal studies. But with reference to ESC and iPSC several methodical and ethical controversies and disadvantages exist, which might favour the clinical application of nPSC.

Conclusion: Stem cells are going to prove beneficial in the treatment of age-related macular degeneration. Different stem cell classes are considered of which the natural pluripotent stem cells might be the most feasible option for clinical application.